With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1334177-86-4,1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid,as a common compound, the synthetic route is as follows.
(d) 4-((2S, 5S) -37-(2, 5-dioxo-2, 5-dihydro- 1 H-pyrrol- 1 -yl) -5-isopropyl-2-methyl-4, 7, 35-trioxo- 10, 13, 16, 19, 22, 25, 28, 31 -octaoxa-3, 6, 34-triazaheptatriacontanamido)benzyl (3-(((S)-8-((5- (((S)- 7-methoxy-2-methyl-5-oxo-5, 11 a-dihydro- 1 H-benzo[e ]pyrrolo[1 , 2-a ][1 , 4 ]diazepin-8- yl)oxy)pentyl)oxy)-2-methyl-5-oxo-5, 11 a-dihydro-1 H-benzo[e]pyrrolo[1 ,2-a][1 ,4]diazepin-7- yl)oxy)propyl)carbamate (4) 1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide (EDCI, 15 mg, 0.080 mmol, 1.1 eq) was added to a solution of crude 3 (0.077 mmol) and Mal-(PEG)8-acid (48 mg, 0.080 mmol, 1 .1 eq) in dry dichloromethane (2 ml_). The reaction was degassed three times with Argon and stirred for 2 hours and the presence of starting material was no longer observed by LC/MS. The reaction was diluted with dichloromethane and washed sequentially with water and brine. The organic phase was dried over magnesium sulphate filtered and excess dichloromethane removed by rotary evaporation under reduced pressure. The resulting residue was subjected to flash column chromatography (silica gel; 100% chloroform to 10% methanol in chloroform). Pure fractions were collected and combined and excess eluent was removed by rotary evaporation under reduced pressure to give the desired product (40mg). This residue was then purified further by preparative HPLC (3.7 mg, 31 % over 2 steps). LC/MS 1.40 min, (ES+) m/z (relative intensity) 1521.95 [M + H]+. 1H NMR (400 MHz, CDCI3) delta 8.72 (s, 1 H), 7.83 (s, 1 H), 7.80 (d, J = 3.9 Hz, 1 H), 7.63 – 7.61 (m, 2H), 7.47 (d, J = 8.3 Hz, 2H), 7.26 (br, 2H), 6.77 – 6.75 (m, 4H), 6.69 (s, 2H), 5.02 (s, 2H), 4.64 – 4.62 (m, 2H), 4.24 – 4.21 (m, 4H), 4.19 – 3.95 (m, 4H), 3.89 (s, 2H), 3.86 – 3.75 (m, 4H), 3.63 (br, 32H), 3.53 – 3.33 (m, 8H), 3.18 – 3.14 (m, 2H), 2.98 – 2.94 (m, 2H), 2.53 – 5.49 (m, 3H), 2.03 (s, 2H), 1.83 (br, 10H), 1 .56 (br, 2H), 1.42 (s, 3H), 1.05 – 0.90 (m, 6H).
The synthetic route of 1334177-86-4 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; MEDIMMUNE LIMITED; HOWARD, Philip, Wilson; (203 pag.)WO2016/37644; (2016); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem